Summary
Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
Publications
Journals
Eng PC, Phylactou M, Qayum A, et al., 2024, Obesity-related hypogonadism in women, Endocrine Reviews, Vol:45, ISSN:0079-9963, Pages:171-189
Hope DCD, Ansari S, Choudhury S, et al., 2024, Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: results from a phase 1 randomized clinical trial, Diabetes, Obesity and Metabolism: a Journal of Pharmacology and Therapeutics, Vol:26, ISSN:1462-8902, Pages:1479-1491
Dubash S, Barwick TD, Kozlowski K, et al., 2024, Somatostatin receptor imaging with [18F]FET-bAG-TOCAPET/CT and [68Ga]Ga-DOTA-peptide PET/CT in patientswith neuroendocrine tumors: a prospective, phase 2comparative study, The Journal of Nuclear Medicine, Vol:65, ISSN:0161-5505, Pages:416-422
Khoo B, Tan TM-M, 2024, GLP-1 analogue therapy for obesity in people from Asia., Lancet Diabetes Endocrinol, Vol:12, Pages:153-154
Kyriacou C, Kapur S, Jeyapala S, et al., 2024, Beta-human chorionic gonadotrophin point of care testing for the management of pregnancy of unknown location., Reprod Biomed Online, Vol:48